Companies: 10,795·Total market cap: $144.5T

Belite Bio, Inc

Belite Bio, Inc

BLTENASDAQHealthcare● Active

$143.35

$-1.11(-0.77%)

Market Cap$5.7B

P/E Ratio—

52W High$200

52W Low$56.1

Avg Volume165K

Open$142.00

Beta-1.24

股票排行：Biotechnology·Healthcare·查看全部市值排行 →

Belite Bio, Inc（BLTE）股票概览

关键指标与盈利、估值、营收、股息等标签页深链。

FMP · BLTE · 截至 Jun 8, 2026

关键指标

EPS (TTM)$-2.55Earnings history

PE Ratio (TTM)—PE Ratio deep dive

Revenue (TTM)0.00Full revenue history

Dividend Yield不分红Dividend history

Shares Outstanding33.5MShares outstanding history

Next EarningsAug 10, 2026Est.Earnings history

探索 Belite Bio, Inc 数据

分析师预测$208 · Buy

股息不分红

盈利EPS $-2.31-95.76%

财务快照

FY 2025Revenue$0.00

202320242025

FY 2025Net Income-$77.6M▼ 114.73% YoY

202320242025

FY 2025EPS$-2.31▼ 95.76% YoY

202320242025

TTM:Revenue: $0.00Net Income: -$90.3MEPS: $-2.55View income statement →

分析师评级与目标价

Buy6 位分析师

Strong Buy

0

Buy

6

Hold

0

Sell

0

Strong Sell

0

12-Month Price Target

$191.00Low

$143.35Current

$208.00Avg Target上涨空间 45.10%

$217.00High

合计: 6 · 买入占比: 100.0%

根据过去 3 个月内 6 位华尔街分析师，BLTE 共识评级为 Buy，12 个月平均目标价 $208.00 （较现价 $143.35 上涨空间 45.10%）。

竞争对手与同行

#TickerCompanyPriceChangeMkt Cap

Belite Bio, Inc

$143.35-0.77%$5.7B #2

ACADIA Pharmaceuticals Inc.

$21.56-0.74%$3.7B #3

ADMA Biologics, Inc.

$7.97-0.13%$1.8B #4

Arcutis Biotherapeutics, Inc.

$21.23-3.28%$2.7B #5

Crinetics Pharmaceuticals, Inc.

$32.92-4.94%$3.5B #6

Dyne Therapeutics, Inc.

$17.04-7.44%$2.8B

股票表现

1D-0.77%

1W+7.31%

1M-7.44%

3M-17.28%

YTD-10.38%

1Y+133.47%

5Y+1253.64%

关于 Belite Bio, Inc

CEOYu-Hsin Lin

IPO DateApr 29, 2022

Employees25

CountryUS

Websitebelitebio.com

Belite Bio, Inc a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and auto…

Biotechnology HealthcareNASDAQADRUS

关于股票概览与关键数据

Belite Bio, Inc（BLTE）是 Biotechnology 行业的 Healthcare 类公司，于 Apr 29, 2022 在 NASDAQ 上市。截至最近交易日，BLTE 股价为 $143.35，市值约为 $5.7B。过去12个月累计回报 +133.47%，年初至今回报 -10.38%。

根据 6 位华尔街分析师，Belite Bio, Inc 股票共识评级为Buy，12个月平均目标价为 $208.00。2025 财年 Belite Bio, Inc 营收 —，净利润 -$77.6M。更多数据（营收历史、盈利、股息、市盈率）请使用上方标签页。

常见问题

截至最近一个交易日，Belite Bio, Inc（BLTE）股价为 $143.35，在 NASDAQ 上市，52周区间为 $56.10 – $200.00。

BLTE 最新股价BLTE quote todaylive ticker 实时行情

数据来源：Financial Modeling Prep最后更新：Jun 8, 2026本内容不构成投资建议